Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.
Most brands spend more than two weeks producing a marketing email, according to recent research from Litmus. The 2019 State of Email Workflows report was based on data from a survey of more than 3,000 ...
About HIVE Digital Technologies Ltd. HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback